149 related articles for article (PubMed ID: 19913516)
1. Investigating the interaction of McN-A-343 with the M2 muscarinic receptor using its nitrogen mustard derivative.
Suga H; Ehlert FJ
Biochem Pharmacol; 2010 Apr; 79(7):1025-35. PubMed ID: 19913516
[TBL] [Abstract][Full Text] [Related]
2. Investigating the interaction of McN-A-343 with the M muscarinic receptor using its nitrogen mustard derivative and ACh mustard.
Figueroa KW; Suga H; Ehlert FJ
Br J Pharmacol; 2010 Jul; 160(6):1534-49. PubMed ID: 20590642
[TBL] [Abstract][Full Text] [Related]
3. Use of acetylcholine mustard to study allosteric interactions at the M(2) muscarinic receptor.
Suga H; Figueroa KW; Ehlert FJ
J Pharmacol Exp Ther; 2008 Nov; 327(2):518-28. PubMed ID: 18682569
[TBL] [Abstract][Full Text] [Related]
4. Mutagenesis of nucleophilic residues near the orthosteric binding pocket of M1 and M2 muscarinic receptors: effect on the binding of nitrogen mustard analogs of acetylcholine and McN-A-343.
Suga H; Sawyer GW; Ehlert FJ
Mol Pharmacol; 2010 Oct; 78(4):745-55. PubMed ID: 20643905
[TBL] [Abstract][Full Text] [Related]
5. Effects of asparagine mutagenesis of conserved aspartic acids in helix 2 (D2.50) and 3 (D3.32) of M1-M4 muscarinic receptors on the irreversible binding of nitrogen mustard analogs of acetylcholine and McN-A-343.
Suga H; Ehlert FJ
Biochemistry; 2013 Jul; 52(29):4914-28. PubMed ID: 23826889
[TBL] [Abstract][Full Text] [Related]
6. Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors.
Lanzafame AA; Sexton PM; Christopoulos A
Mol Pharmacol; 2006 Aug; 70(2):736-46. PubMed ID: 16709648
[TBL] [Abstract][Full Text] [Related]
7. Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors.
May LT; Avlani VA; Langmead CJ; Herdon HJ; Wood MD; Sexton PM; Christopoulos A
Mol Pharmacol; 2007 Aug; 72(2):463-76. PubMed ID: 17525129
[TBL] [Abstract][Full Text] [Related]
8. Development of a radioligand, [(3)H]LY2119620, to probe the human M(2) and M(4) muscarinic receptor allosteric binding sites.
Schober DA; Croy CH; Xiao H; Christopoulos A; Felder CC
Mol Pharmacol; 2014 Jul; 86(1):116-23. PubMed ID: 24807966
[TBL] [Abstract][Full Text] [Related]
9. Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors.
Lazareno S; Popham A; Birdsall NJ
Mol Pharmacol; 2002 Dec; 62(6):1492-505. PubMed ID: 12435818
[TBL] [Abstract][Full Text] [Related]
10. Tertiary 2-haloethylamine derivatives of the muscarinic agent McN-A-343, [4-[[N-(3-chlorophenyl)carbamoyl]oxy]-2-butynyl]trimethylammonium chloride.
Ringdahl B; Mellin C; Ehlert FJ; Roch M; Rice KM; Jenden DJ
J Med Chem; 1990 Jan; 33(1):281-6. PubMed ID: 2296024
[TBL] [Abstract][Full Text] [Related]
11. A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand.
Valant C; Gregory KJ; Hall NE; Scammells PJ; Lew MJ; Sexton PM; Christopoulos A
J Biol Chem; 2008 Oct; 283(43):29312-21. PubMed ID: 18723515
[TBL] [Abstract][Full Text] [Related]
12. Conversion of N-(2-chloroethyl)-4-piperidinyl diphenylacetate (4-DAMP mustard) to an aziridinium ion and its interaction with muscarinic receptors in various tissues.
Thomas EA; Hsu HH; Griffin MT; Hunter AL; Luong T; Ehlert FJ
Mol Pharmacol; 1992 Apr; 41(4):718-26. PubMed ID: 1569923
[TBL] [Abstract][Full Text] [Related]
13. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor.
Steinfeld T; Mammen M; Smith JA; Wilson RD; Jasper JR
Mol Pharmacol; 2007 Aug; 72(2):291-302. PubMed ID: 17478612
[TBL] [Abstract][Full Text] [Related]
14. Allosteric interaction of the neuromuscular blockers vecuronium and pancuronium with recombinant human muscarinic M2 receptors.
Cembala TM; Forde SC; Appadu BL; Lambert DG
Eur J Pharmacol; 2007 Aug; 569(1-2):37-40. PubMed ID: 17588565
[TBL] [Abstract][Full Text] [Related]
15. The binding of a 2-chloroethylamine derivative of oxotremorine (BM 123) to muscarinic receptors in the rat cerebral cortex.
Ehlert FJ; Jenden DJ
Mol Pharmacol; 1985 Aug; 28(2):107-19. PubMed ID: 3839562
[TBL] [Abstract][Full Text] [Related]
16. Two-state models and the analysis of the allosteric effect of gallamine at the M2 muscarinic receptor.
Ehlert FJ; Griffin MT
J Pharmacol Exp Ther; 2008 Jun; 325(3):1039-60. PubMed ID: 18305010
[TBL] [Abstract][Full Text] [Related]
17. Muscarinic allosteric modulation: M2/M3 subtype selectivity of gallamine is independent of G-protein coupling specificity.
Tränkle C; Kostenis E; Mohr K
Naunyn Schmiedebergs Arch Pharmacol; 2001 Aug; 364(2):172-8. PubMed ID: 11534857
[TBL] [Abstract][Full Text] [Related]
18. The impact of orthosteric radioligand depletion on the quantification of allosteric modulator interactions.
Avlani VA; McLoughlin DJ; Sexton PM; Christopoulos A
J Pharmacol Exp Ther; 2008 Jun; 325(3):927-34. PubMed ID: 18322151
[TBL] [Abstract][Full Text] [Related]
19. Vinburnine decelerates [3H]N-methylscopolamine binding to recombinant human muscarinic M1-M4 acetylcholine receptors.
Maksay G; Bíró T; Kiss B
Eur J Pharmacol; 2004 Jan; 483(2-3):229-32. PubMed ID: 14729111
[TBL] [Abstract][Full Text] [Related]
20. Allosteric site in M2 acetylcholine receptors: evidence for a major conformational change upon binding of an orthosteric agonist instead of an antagonist.
Grossmüller M; Antony J; Tränkle C; Holzgrabe U; Mohr K
Naunyn Schmiedebergs Arch Pharmacol; 2006 Jan; 372(4):267-76. PubMed ID: 16362429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
